Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06964737 · ClinicalTrials.gov registry record · Phase 1
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
A Phase 1 study of Recurrent Malignant Glioma and WHO Grade 3 Glioma, sponsored by Ohio State University Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06964737 is a Phase 1 study of Recurrent Malignant Glioma and WHO Grade 3 Glioma that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 30 participants, above the 25-participant average among 17 other Recurrent Malignant Glioma trials with a reported enrollment target (20% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06964737, a Phase 1 study of Recurrent Malignant Glioma and WHO Grade 3 Glioma, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial tests the safety, side effects, and best dose of anti-glycoprotein-A repetitions predominant (GARP) chimeric antigen receptor (CAR) T cell therapy and how well it works in treating patients with grade III or IV gliomas that have come back after a period of improvement (recurrent). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein, such as GARP, on the patient's tumor cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain tumors. Giving anti-GARP CAR T cell therapy may be safe, tolerable, and/or effective in treating patients with recurrent grade III or IV gliomas.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Echocardiography Test
- PROCEDURE Chest Radiography
- BIOLOGICAL Anti-GARP Chimeric Antigen Receptor-T Cells
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-05-21 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06964737
The ClinicalTrials.gov registry entry for NCT06964737 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 25-participant average among 17 other Recurrent Malignant Glioma trials with a reported enrollment target (20% higher). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Recurrent Malignant Glioma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06964737 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06964737 about?
NCT06964737 is a clinical study titled "Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas". This phase I trial tests the safety, side effects, and best dose of anti-glycoprotein-A repetitions predominant (GARP) chimeric antigen receptor (CAR) T cell therapy and how well it works in treating patients with grade III or IV gliomas that have come back after a period of improvement (recurrent)....
What is the current status of trial NCT06964737?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-05-21. Estimated completion is 2026-12-31.
What conditions does trial NCT06964737 study?
This clinical trial studies the following conditions: Recurrent Malignant Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma, Recurrent WHO Grade 4 Glioma, Recurrent WHO Grade 3 Glioma.
What interventions are being tested in trial NCT06964737?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Echocardiography Test (PROCEDURE), Chest Radiography (PROCEDURE), Anti-GARP Chimeric Antigen Receptor-T Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT06964737?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06964737 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
RECRUITING · Phase 1
-
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RECRUITING · Phase 1
-
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
RECRUITING · Phase 1
-
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
ACTIVE NOT RECRUITING · Phase 1
-
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.